AstraZeneca plc (AZN) Rating Reiterated by Deutsche Bank AG
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by Deutsche Bank AG in a research report issued on Tuesday. They presently have a GBX 6,200 ($76.73) price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s price objective points to a potential upside of 25.04% from the stock’s current price.
AZN has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued a “neutral” rating and set a GBX 4,900 ($60.64) price target (up previously from GBX 4,800 ($59.41)) on shares of AstraZeneca plc in a research report on Monday, August 8th. Jefferies Group set a GBX 5,400 ($66.83) price target on AstraZeneca plc and gave the stock a “neutral” rating in a research report on Monday, August 8th. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research report on Tuesday, August 9th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.50) price target on AstraZeneca plc and gave the stock a “sell” rating in a research report on Wednesday, August 10th. Finally, Beaufort Securities reissued a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. AstraZeneca plc presently has an average rating of “Hold” and a consensus price target of GBX 4,960.13 ($61.39).
AstraZeneca plc (LON:AZN) opened at 4963.52 on Tuesday. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company’s market cap is GBX 62.79 billion. The company’s 50 day moving average price is GBX 5,002.62 and its 200 day moving average price is GBX 4,463.11.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.